FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2055063721> ?p ?o ?g. }

• W2055063721 endingPage "756" @default.
• W2055063721 startingPage "752" @default.
• W2055063721 abstract "SummaryBackground: Venous thromboembolism (VTE) is a multi‐factorial disease. Extensive thrombophilia screening is costly and often inconclusive. Simple laboratory methods are required to predict the risk of recurrence. Objective: To assess if measurement of activated partial thromboplastin time (APTT) allows stratification of patients with VTE into high‐ and low‐risk categories with regard to recurrence. Patients and methods: We prospectively followed 918 patients with a first unprovoked VTE and studied the relationship between recurrence and an APTT after discontinuation of anticoagulation. APTT was expressed as a ratio of test to reference coagulation times. Study endpoint was symptomatic recurrent VTE. Results: Venous thromboembolism recurred in 101 (11%) patients. Patients without recurrence had a greater APTT ratio than those with recurrence (0.97 ± 0.09 vs. 0.93 ± 0.09, P = 0.001). After 4 years, probability of recurrent VTE was 8.5% (95% CI: 5.5–11.5%) among patients with a ratio equal to or > 0.95 and 15.6% (95% CI: 11.4–19.9%) among patients with a lower ratio (P = 0.005). Compared with patients with an APTT ratio < 0.95, the relative risk (RR) of recurrence among patients with a ratio equal to or > 0.95 was 0.56 (95% CI: 0.38–0.84, P = 0.005) before and 0.58 (95% CI: 0.39–0.87, P = 0.009) after adjustment for sex, age, factor V Leiden, and factor II G20210A. Conclusions: Measurement of APTT allows stratification of patients with VTE into high‐ and low‐risk categories with regard to recurrence. Background: Venous thromboembolism (VTE) is a multi‐factorial disease. Extensive thrombophilia screening is costly and often inconclusive. Simple laboratory methods are required to predict the risk of recurrence. Objective: To assess if measurement of activated partial thromboplastin time (APTT) allows stratification of patients with VTE into high‐ and low‐risk categories with regard to recurrence. Patients and methods: We prospectively followed 918 patients with a first unprovoked VTE and studied the relationship between recurrence and an APTT after discontinuation of anticoagulation. APTT was expressed as a ratio of test to reference coagulation times. Study endpoint was symptomatic recurrent VTE. Results: Venous thromboembolism recurred in 101 (11%) patients. Patients without recurrence had a greater APTT ratio than those with recurrence (0.97 ± 0.09 vs. 0.93 ± 0.09, P = 0.001). After 4 years, probability of recurrent VTE was 8.5% (95% CI: 5.5–11.5%) among patients with a ratio equal to or > 0.95 and 15.6% (95% CI: 11.4–19.9%) among patients with a lower ratio (P = 0.005). Compared with patients with an APTT ratio < 0.95, the relative risk (RR) of recurrence among patients with a ratio equal to or > 0.95 was 0.56 (95% CI: 0.38–0.84, P = 0.005) before and 0.58 (95% CI: 0.39–0.87, P = 0.009) after adjustment for sex, age, factor V Leiden, and factor II G20210A. Conclusions: Measurement of APTT allows stratification of patients with VTE into high‐ and low‐risk categories with regard to recurrence." @default.
• W2055063721 created "2016-06-24" @default.
• W2055063721 creator A5015899523 @default.
• W2055063721 creator A5034952955 @default.
• W2055063721 creator A5053093013 @default.
• W2055063721 creator A5060041875 @default.
• W2055063721 creator A5075974505 @default.
• W2055063721 creator A5091294843 @default.
• W2055063721 date "2006-04-01" @default.
• W2055063721 modified "2023-10-18" @default.
• W2055063721 title "Prediction of recurrent venous thromboembolism by the activated partial thromboplastin time" @default.
• W2055063721 cites W1531288520 @default.
• W2055063721 cites W1777100975 @default.
• W2055063721 cites W1978280229 @default.
• W2055063721 cites W1990107586 @default.
• W2055063721 cites W1992159512 @default.
• W2055063721 cites W2001692920 @default.
• W2055063721 cites W2012519169 @default.
• W2055063721 cites W2014569258 @default.
• W2055063721 cites W2063532159 @default.
• W2055063721 cites W2073175019 @default.
• W2055063721 cites W2073192852 @default.
• W2055063721 cites W2074475417 @default.
• W2055063721 cites W2101311135 @default.
• W2055063721 cites W2131728148 @default.
• W2055063721 cites W2133607184 @default.
• W2055063721 cites W2150825057 @default.
• W2055063721 cites W2165133565 @default.
• W2055063721 cites W2327141264 @default.
• W2055063721 cites W2331935930 @default.
• W2055063721 cites W2332640098 @default.
• W2055063721 cites W2337281790 @default.
• W2055063721 cites W2417603793 @default.
• W2055063721 cites W2568332688 @default.
• W2055063721 cites W41698588 @default.
• W2055063721 cites W4236382869 @default.
• W2055063721 cites W4249053801 @default.
• W2055063721 cites W4293241248 @default.
• W2055063721 cites W4296981399 @default.
• W2055063721 cites W74544974 @default.
• W2055063721 doi "https://doi.org/10.1111/j.1538-7836.2006.01868.x" @default.
• W2055063721 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16634742" @default.
• W2055063721 hasPublicationYear "2006" @default.
• W2055063721 type Work @default.
• W2055063721 sameAs 2055063721 @default.
• W2055063721 citedByCount "70" @default.
• W2055063721 countsByYear W20550637212012 @default.
• W2055063721 countsByYear W20550637212013 @default.
• W2055063721 countsByYear W20550637212014 @default.
• W2055063721 countsByYear W20550637212015 @default.
• W2055063721 countsByYear W20550637212016 @default.
• W2055063721 countsByYear W20550637212017 @default.
• W2055063721 countsByYear W20550637212018 @default.
• W2055063721 countsByYear W20550637212019 @default.
• W2055063721 countsByYear W20550637212020 @default.
• W2055063721 countsByYear W20550637212021 @default.
• W2055063721 countsByYear W20550637212022 @default.
• W2055063721 crossrefType "journal-article" @default.
• W2055063721 hasAuthorship W2055063721A5015899523 @default.
• W2055063721 hasAuthorship W2055063721A5034952955 @default.
• W2055063721 hasAuthorship W2055063721A5053093013 @default.
• W2055063721 hasAuthorship W2055063721A5060041875 @default.
• W2055063721 hasAuthorship W2055063721A5075974505 @default.
• W2055063721 hasAuthorship W2055063721A5091294843 @default.
• W2055063721 hasBestOaLocation W20550637211 @default.
• W2055063721 hasConcept C126322002 @default.
• W2055063721 hasConcept C141071460 @default.
• W2055063721 hasConcept C156957248 @default.
• W2055063721 hasConcept C16124881 @default.
• W2055063721 hasConcept C168563851 @default.
• W2055063721 hasConcept C203092338 @default.
• W2055063721 hasConcept C2778261982 @default.
• W2055063721 hasConcept C2778382381 @default.
• W2055063721 hasConcept C2778715236 @default.
• W2055063721 hasConcept C2780842393 @default.
• W2055063721 hasConcept C2780868729 @default.
• W2055063721 hasConcept C2991741193 @default.
• W2055063721 hasConcept C50440223 @default.
• W2055063721 hasConcept C71924100 @default.
• W2055063721 hasConcept C90924648 @default.
• W2055063721 hasConceptScore W2055063721C126322002 @default.
• W2055063721 hasConceptScore W2055063721C141071460 @default.
• W2055063721 hasConceptScore W2055063721C156957248 @default.
• W2055063721 hasConceptScore W2055063721C16124881 @default.
• W2055063721 hasConceptScore W2055063721C168563851 @default.
• W2055063721 hasConceptScore W2055063721C203092338 @default.
• W2055063721 hasConceptScore W2055063721C2778261982 @default.
• W2055063721 hasConceptScore W2055063721C2778382381 @default.
• W2055063721 hasConceptScore W2055063721C2778715236 @default.
• W2055063721 hasConceptScore W2055063721C2780842393 @default.
• W2055063721 hasConceptScore W2055063721C2780868729 @default.
• W2055063721 hasConceptScore W2055063721C2991741193 @default.
• W2055063721 hasConceptScore W2055063721C50440223 @default.
• W2055063721 hasConceptScore W2055063721C71924100 @default.
• W2055063721 hasConceptScore W2055063721C90924648 @default.
• W2055063721 hasIssue "4" @default.
• W2055063721 hasLocation W20550637211 @default.
• W2055063721 hasLocation W20550637212 @default.

• next